Ultra-high speed AO-OCT clinical system to image ganglion cells and microglia

Physical Sciences Inc. (PSI), in collaboration with Massachusetts Eye and Ear (MEE), and Joslin Diabetes Center (JDC), has been awarded a research program from the National Institutes of Health (NIH) to develop a clinical tool able to routinely image retinal ganglion cells (RGCs) and to characterize microglia spatial distribution and temporal dynamics in live human eyes using a label-free adaptive optics (AO) imaging approach for improved diagnosis and treatment of glaucoma and diabetic retinopathy (DR).

PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for the ophthalmic research market that gives us a competitive advantage in developing and maturing this platform that enables routine clinical imaging of human subjects. The successful program and subsequent commercial development will provide clinicians with high performance retinal imaging for glaucoma and DR investigations at a lower cost and improved functionality superior to other non-AO retinal imagers. Early adaptors of this technology within the research community will grow our understanding of vision and its disruption by glaucoma and DR and will investigate the effects of new drugs and therapies. The ability to visualize ganglion and macrophage cells without fluorescent labeling in the human eye represents an important advance for both ophthalmology and neuroscience, which will lead to identification of novel disease biomarkers and new avenues of exploration in disease progression.

For more information, contact:

Mr. William Kessler
Vice President, Applied Optics
kessler@psicorp.com
Physical Sciences Inc.
Telephone: (978) 689-0003